Hemophilia
HA Monkey model is induced by injection of excessive FVIII-neutralization antibody. Modeling animals display FVllI deficient coagulation disorder.
This model of Hemophilia A is established through the targeted administration of high-titer neutralizing anti-FVIII antibodies, effectively inducing a state of acquired Factor VIII deficiency. By neutralizing endogenous clotting factors, this non-human primate (NHP) model accurately recapitulates the severe coagulopathy observed in clinical Hemophilia A.
NHP Models of Hemophilia A (HA)
- Induction of Coagulopathy: Systematic injection of anti-FVIII antibodies results in a profound FVIII-deficient coagulation disorder, mimicking the pathophysiology of human patients with high-titer inhibitors./dd>
- Hemostatic Impairment: Subjects demonstrate significant prolongation of activated partial thromboplastin time (aPTT) and impaired thrombin generation kinetics, providing objective benchmarks for disease severity.
- Clinical Phenotype: The model exhibits characteristic bleeding tendencies and compromised fibrin clot stability, essential for evaluating the efficacy of bypass agents and novel factor-replacement therapies.
Figure 1. Post-modeling (D0-0h), aPTT in the model group prolonged to 3-4 times pre-modeling levels, demonstrating coagulopathy.
Figure 2. Coagulopathy in chronic hemophilia models induced by repeated modeling agent injections can be maintained for up to eight weeks.
-
-
Topgene Biotechnology -
marketing@topgenebio.com -
